A Real-World Retrospective Cohort Study Characterizing Healthcare Resource Utilization and Costs Among Patients With MMN in the United States
Author(s)
Clémence Arvin-Berod, PharmD1, CECILE BLEIN, PhD2, Sergio Barrera-Sierra Barrera-Sierra, MD3, Jamie Wood, PharmD3, Charlotte E. Ward, PhD4, Divya Nagpal, BS5, Kartik Wadhwa, BS5, Varun Gupta, BS5, Dustin Nowacek, MD6.
1argenx, Zwijnaarde, Belgium, 2Argenx, Zwijnaarde, Belgium, 3argenx, Boston, MA, USA, 4Consultant, ZS Associates, Concord, NH, USA, 5ZS Associates, Gurugram, India, 6Argenx, Boston, MA, USA.
1argenx, Zwijnaarde, Belgium, 2Argenx, Zwijnaarde, Belgium, 3argenx, Boston, MA, USA, 4Consultant, ZS Associates, Concord, NH, USA, 5ZS Associates, Gurugram, India, 6Argenx, Boston, MA, USA.
OBJECTIVES: Multifocal Motor Neuropathy (MMN) is a rare, complement-driven, immune-mediated motor neuropathy marked by asymmetric limb weakness without sensory loss, often leading to substantial disability. Its economic impact is considerable, in part due to symptom overlap with other conditions, which contributes to delayed diagnosis and increased treatment costs. This study examines real-world resource utilization and costs associated with MMN, offering insights into its financial burden on healthcare systems and patients.
METHODS: A retrospective cohort study was conducted using a US claims dataset (Komodo Health, Jan 2016-Mar 2024). Adult MMN patients were included if they had ≥2 MMN ICD-10 diagnoses and ≥1 relevant diagnostic test prior to the second diagnosis, along with continuous enrollment one year pre-index. Healthcare costs and utilization were assessed for the 12 months before and after the index date.
RESULTS: We identified 330 MMN patients. Median annual all-cause medical costs rose from $9K (IQR: $4K-$20K) pre-index to $61K (IQR: $11K-$144K) post-index. Median homecare costs increased from $16K (IQR: $0K-$115K) to $63K (IQR: $10K-$137K), and median outpatient costs rose from $6K (IQR: $3K-$12K) to $16K (IQR: $5K-$67K). Inpatient, emergency department, and pharmacy costs remained relatively low and stable. Median visit frequency also rose, particularly for outpatient (18 to 26 visits) and homecare (4 to 12 visits) services.
CONCLUSIONS: The economic burden and healthcare utilization associated with MMN are primarily driven by outpatient and homecare services. These services, which include regular treatments and ongoing care, contribute significantly to the overall costs. The findings highlight the substantial financial impact of managing MMN and the broader economic challenges faced by patients, emphasizing the need for strategies to alleviate these burdens.
METHODS: A retrospective cohort study was conducted using a US claims dataset (Komodo Health, Jan 2016-Mar 2024). Adult MMN patients were included if they had ≥2 MMN ICD-10 diagnoses and ≥1 relevant diagnostic test prior to the second diagnosis, along with continuous enrollment one year pre-index. Healthcare costs and utilization were assessed for the 12 months before and after the index date.
RESULTS: We identified 330 MMN patients. Median annual all-cause medical costs rose from $9K (IQR: $4K-$20K) pre-index to $61K (IQR: $11K-$144K) post-index. Median homecare costs increased from $16K (IQR: $0K-$115K) to $63K (IQR: $10K-$137K), and median outpatient costs rose from $6K (IQR: $3K-$12K) to $16K (IQR: $5K-$67K). Inpatient, emergency department, and pharmacy costs remained relatively low and stable. Median visit frequency also rose, particularly for outpatient (18 to 26 visits) and homecare (4 to 12 visits) services.
CONCLUSIONS: The economic burden and healthcare utilization associated with MMN are primarily driven by outpatient and homecare services. These services, which include regular treatments and ongoing care, contribute significantly to the overall costs. The findings highlight the substantial financial impact of managing MMN and the broader economic challenges faced by patients, emphasizing the need for strategies to alleviate these burdens.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE28
Topic
Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Neurological Disorders, Rare & Orphan Diseases, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)